Our knowledge about the genetics of myelodysplastic syndromes (MDS) and related
myeloid disorders has been dramatically improved during the past decade, in which …

Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly
2 decades ago through the identification of rare subpopulations of engrafting cells in …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the proliferation and aberrant differentiation of immature clonal myeloid cells. The …

Relapse remains the most common cause of treatment failure for patients with acute myeloid
leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a …

Abstract Nucleophosmin-1 mutations (NPM1+) occur in∼ 30% of acute myeloid leukemia
(AML) patients. Although typically associated with favorable prognosis, the beneficial impact …

Our understanding of the perturbation of normal cellular differentiation hierarchies to create
tumor-propagating stem cell populations is incomplete. In human acute myeloid leukemia …

Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which
blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor …

The nonobese diabetic/severe combined immunodeficient (NOD/SCID) assay is the current
model for assessment of human normal and leukemic stem cells. We explored why 51% of …

Mutation of the nucleophosmin (NPM) gene has been reported as the most frequent
mutation in acute myeloid leukemia (AML), especially in the presence of a normal karyotype …

The results from the RATIFY trial (ClinicalTrials. gov: NCT00651261; CALGB 10603)
showed that midostaurin combined with standard chemotherapy significantly improved …